Transcriptomics

Dataset Information

0

Radium 223 induces transient functional bone marrow toxicity


ABSTRACT: Radium 223 (Rad223) is a bone-seeking, alpha-particle-emitting radionuclide approved for the treatment of patients with metastatic castration resistant prostate cancer and is currently being tested in a variety of clinical trials for primary and metastatic cancers to bone. Clinical evaluation of Rad223 hematologic safety showed a significantly increased rate of neutropenia and thrombocytopenia in patients, hinting at myelosuppression as side effect. In this study we present a preclinical approach to investigate the consequences of Rad223 treatment on bone marrow biology. Rad223 accumulated in bones and induced confined radiation damage, followed by progressive replacement of the impaired areas with adipocyte infiltration, as monitored by three-dimensional multiphoton microscopy, ex vivo. Flow cytometry and single cell transcriptomic analyses on bone marrow hematopoietic populations revealed transient, non-specific Rad223-mediated cytotoxicity on resident populations, including stem, progenitor and mature leukocytes. This was paralleled by a significant decrease of white blood cells and platelets in peripheral blood, which was overcome within 40 days post-treatment. Rad223 exposure did not impair full hematopoietic reconstitution, suggesting that the bone marrow function is not permanently hampered. Our results provide a comprehensive explanation of Rad223 reversible effects on bone marrow cells and exclude long-term myelotoxicity, supporting its safety during treatment of patients at both early and late disease stages.

ORGANISM(S): Mus musculus

PROVIDER: GSE176195 | GEO | 2023/12/12

REPOSITORIES: GEO

Similar Datasets

2019-08-13 | BIOMD0000000793 | BioModels
2019-08-13 | BIOMD0000000795 | BioModels
2013-05-22 | E-GEOD-42548 | biostudies-arrayexpress
2013-05-22 | E-GEOD-42254 | biostudies-arrayexpress
2013-05-22 | GSE42548 | GEO
2013-05-22 | GSE42254 | GEO
2021-09-16 | GSE160102 | GEO
2013-10-22 | GSE41801 | GEO
2024-03-03 | GSE220946 | GEO
2022-08-03 | GSE193468 | GEO